In fact, overexpression of p21 has been previously shown to desensitize LNCaP cells to docetaxel treatment, identifying the p38/p53/p21 signaling axis as an important determinant of susceptibility towards docetaxel-induced apoptosis in prostate cancer [54]. Here, CDKN1A is linked to prostate carcinoma.